Psychedelic Assisted Psychotherapy

Mindspace has become a pioneer in Canada in the emerging field of psychedelic-assisted psychotherapy in recent years. Our recent news that we will be joining the Numinus Wellness team means we will be delivering best-in-class, leading-edge mental health solutions nationwide in 2021, with the intention to include MDMA and psilocybin-assisted psychotherapy

In 2019 we hosted one of the first training programs in Canada for clinicians wanting to learn more about helping their clients work safely with psychedelics, and launched our Psychedelic Harm Reduction and Integration program, and in late 2020 we began offering ketamine-assisted psychotherapy. Our psychedelics team continues to push this discipline forward and facilitate continuing education efforts with a number of partners throughout North America.

Ketamine-Assisted Psychotherapy

Ketamine-Assisted Psychotherapy

There is an increasing body of evidence that suggests that the supervised use of ketamine can be effective as a treatment for depression. Ketamine occupies a unique position in the psychedelic landscape from a regulatory perspective and can now be prescribed to address treatment-resistant depression. Mindspace has assembled a multi-disciplinary team of health care professionals in order to offer this service to our clients.

Psychedelic Harm Reduction and Integration

Psychedelic Harm Reduction and Integration

Mindspace holds a harm reduction position in response to the growing public interest in psychedelics to support the mental health and well-being of individuals who intend to or have had psychedelic experiences. While Mindspace neither condemns nor encourages psychedelic use, we believe that with proper education and integration support, the potential benefits of psychedelic use can be increased, and the risks associated with it reduced.

Psychedelic-Assisted Psychotherapy with MDMA and Psilocybin

Psychedelic-Assisted Psychotherapy with MDMA and Psilocybin

Mindspace is pleased to be at the forefront of psychedelic-assisted psychotherapy solutions in Canada. Specifically, in light of Health Canada’s recently announced notice of intent to revise its Special Access Programme, should Health Canada ultimately allow for SAP applications, we expect to eventually be offering both psilocybin and MDMA for a number of indications, including depression, PTSD and anxiety.

Our Team

From the Blog